Halozyme Therapeutics, Inc. (HALO) — Executive Compensation
Fiscal year ended December 2025
This page summarizes Halozyme Therapeutics, Inc. (HALO) named executive officer compensation from the most recent SEC DEF 14A proxy statement. Helen I Torley (CEO) received $23,166,223 in reported total compensation@if($peoPaid !== null), with $39,731,590 "actually paid" under the SEC pay-versus-performance rule. @endif Total shareholder return for the period was 157.57.
Frequently asked questions
Who is the CEO of HALO and how much are they paid?
Helen I Torley serves as CEO of Halozyme Therapeutics, Inc.. For fiscal year ending December 2025, reported total compensation was $23,166,223.
What is included in executive compensation?
SEC Summary Compensation Table figures include base salary, cash bonuses, stock awards (grant-date fair value), option awards, non-equity incentive plan compensation, pension value changes, and all other compensation. "Actually Paid" compensation follows the newer SEC pay-versus-performance rule and reflects realized value.
What is pay-versus-performance?
The SEC pay-versus-performance disclosure requires companies to show the relationship between executive pay "actually paid" and total shareholder return (TSR) over recent fiscal years, so investors can evaluate pay alignment.